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ABSTRACT 
Vascular endothelial growth factor (VEGF) has been shown to be an endothelial cell-specific mitogen and an 
angiogenic inducer in a variety of in vitro and in vivo models. Furthermore, it has been demonstrated to 
increase retinal vessel permeability by increasing the phosphorylation of tight junction proteins. Recent 
work has found elevated levels of VEGF in ocular fluids of patients with proliferative diabetic retinopathy 
(PDR). Thus, it makes sense to consider anti-VEGF treatments in the management of PDR. The purpose of 
the current research is to determine if intravitreal bevacizumab as anti-VEGF is helpful in the management 
of complications of PDR. 
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INTRODUCTION  
Dietary habits and an increase in sedentarism are the 
main culprits of a worldwide epidemic in diabetes 
mellitus (DM). In the year 2010, more than 285 million 
people suffered from DM. The World Health 
Organization has estimated that by the year 2030 there 
will be 370 million persons affected with DM in the 
world, and every one of them will be at risk of developing 
diabetic retinopathy (DR) [1].  Other studies predict that 
the number will be even higher at 439 million persons 
affected with DM in the world [2]. Prior to the advent of 
panretinal photocoagulation (PRP), proliferative diabetic 
retinopathy (PDR) was the main cause of diabetic 
blindness.  
More than 60 years ago, Michaelson speculated on the 
presence of a Factor X that was capable of inducing 
retinal angiogenesis or neovascularization [3]. Vascular 
endothelial growth factor (VEGF) appears to be the most 
likely candidate to be Michaelson’s factor X and the main 
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molecular mediator in diabetic retinopathy. The 
underlying problem in diabetic patients is the progressive 
retinal ischemia caused by the metabolic disarray of 
chronic hyperglycemia. Hypoxia is a major inducer of 
VEGF gene transcription. VEGF has been shown to be an 
endothelial cell-specific mitogen and an angiogenic 
inducer in a variety of in vitro and in vivo models [4]. 
Furthermore, it has been demonstrated to increase 
retinal vessel permeability by increasing the 
phosphorylation of tight junction proteins. Recent work 
has found elevated levels of VEGF in ocular fluids of 
patients with PDR [5-10]. Thus it makes sense to consider 
anti-VEGF treatments in the management of diabetic 
macular edema (DME) and PDR.  
Several anti-VEGF agents are currently available in clinical 
practice. Pegaptanib sodium (Macugen®, Eyetech, NY,  
USA) is an aptamer against the VEGF-165 isoform [11]. 
Ranibizumab (Lucentis®, Genentech, San Francisco, CA, 
USA) is a fragment of a humanized monoclonal antibody 
against all VEGF isoforms [12]. Bevacizumab (Avastin®, 
Genentech, San Francisco, CA, USA) is a humanized, 
recombinant monoclonal IgG antibody that binds and 
inhibits all VEGF isoforms [13-15]. Aflibercept, previously 
known as VEGF-Trap eye (Eylea®, Regeneron 
Pharmaceutics Inc., Tarrytown, NY) is a recombinant 
fusion protein that consists of portions of human VEGF 
receptors 1 and 2 that allows it to bind to VEGF-A, VEGF-
B and placental growth factor [16]. All of these agents 
have been used to differing extents in the management 
of DME and PDR [17-27]. However, there is a 
tremendous difference in price between these drugs. 
Bevacizumab costs only a small fraction of Ranibizumab, 
Pegaptanib or Aflibercept. If Bevacizumab were not 
available and research for its off-label use not 
performed, many diabetics in developing countries 
would not have enjoyed the benefit of this remarkable 
medication. 
We have long been interested in studying the effects of 
intravitreal bevacizumab in several vitreoretinal 
conditions including DME and PDR [20-27]. Given the off-
label nature of intravitreal bevacizumab, its 
pharmacokinetics and safety have not been as 
thoroughly studied as other approved similar drugs. We 
have previously shown in an open label uncontrolled 
clinical study that intravitreal bevacizumab appears to be 
safe and well tolerated [28]. A recent randomized clinical 
trial has shown no differences with regards to systemic 
side effects between intravitreal ranibizumab and 
intravitreal bevacizumab [29].  
 
HYPOTHESIS 
Intravitreal bevacizumab (IVB) may decrease retinal 
neovascularization in patients with PDR after six months 
of follow-up. However, the effect may decrease at 24 
months of follow up due to tachyphylaxis, and pan-
retinal photocoagulation and/or vitrectomy will be 
necessary.  
 
DISCUSSION 
The underlying problem in diabetic retinopathy is 
progressive retinal ischemia caused by the metabolic 
disarray of chronic hyperglycemia. If the hyperglycemia is 
not controlled, up-regulation of growth factors and 
cytokines occur. VEGF is an important, if not the most 
important cytokine involved. Activation of the VEGF-
receptor pathway triggers a network of signaling 
processes that promotes endothelial cell growth, 
migration, survival from pre-existing vessels, 
differentiation and mobilization of endothelial progenitor 
cells from the bone marrow into the peripheral 
circulation. An increase in vascular permeability followed 
by angiogenesis leads to retinal, optic disc and even 
anterior segment neovascularization [30].  
PRP has been the mainstay of treatment for PDR, and its 
suppressive effect on ocular neovascularization has been 
well documented [31]. However, substantial regression 
of new vessels may take weeks after completion of PRP, 
and in up to one-third of cases, new vessels continue to 
grow despite initial PRP [32]. In these cases, vitreous 
hemorrhage may induce visual loss and prevent the need 
for complete laser. Moreover, macular edema may 
increase after PRP and cause transient or persistent 
visual loss [33]. Neovascularization on and around the 
optic disc (NVD) and vitreous hemorrhage were found to 
be more frequently associated with severe visual loss 
despite PRP in the Diabetic Retinopathy Study (DRS) and 
ETDRS [34-35]. Long intervals between PRP sessions and 
the variable amount of time required for a favorable 
response may increase the incidence of complications 
due to the progression of PDR [35]. In fact, a single 
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episode of PRP or shorter intervals between PRP 
episodes, although desirable in severe PDR, and when 
the patient must travel long distances for treatment, are 
often associated with acute visual disturbances due to 
exudative choroidal detachment, retinal detachment, 
and macular edema [32,36-38]. Several reports 
document the regression of retinal neovascularization 
following the administration of intravitreal anti-VEGF 
compounds in PDR [39-41].  
We previously conducted a retrospective study in 43 
eyes of 39 patients with PDR that had persistent retinal 
neovascularization and concomittant DME [24]. Of the 
total of 43 eyes, 31 (72.1%) eyes had been previously 
treated with scatter photocoagulation at least six months 
before intravitreal bevacizumab, no eyes had prior focal/ 
grid laser photocoagulation, and no eyes had a previous 
intravitreal triamcinolone injection. Twenty-four (55.8%) 
eyes were treated with an intravitreal injection of 1.25 
mg and 19 (44.2%) eyes were treated with 2.5 mg of 
bevacizumab.  
At the end of the two year follow-up (Restrepo et al. The 
Association for Research in Vision and Ophthalmology 
Annual Meeting 2010. Fort Lauderdale, FL. Unpublished 
data), the mean baseline BCVA of logMAR = 0.94 ± 0.38  
ETDRS (20/176) improved to a mean BCVA of logMAR = 
0.67 ±  0.39 ETDRS (20/94) (p < 0.0005). Final BCVA 
analysis by sub-groups demonstrated that 35 (81.4%) 
eyes remained stable, five (11.6%) eyes improved two or 
more ETDRS lines of BCVA, and three (7%) eyes 
decreased two or more ETDRS lines of BCVA. These visual 
improvements were accompanied by a statistically 
significant decrease in OCT CMT [23-24].  
 Of the 43 eyes, 17 (39.5%) eyes showed total regression 
of retinal neovascularization. Fifteen (34.9%) eyes 
demonstrated partial regression of retinal 
neovascularization, and 11 (25.6) eyes showed no 
regression of retinal neovascularization. When divided by 
type of retinal neovascularization, of the total of 43 eyes, 
15 (34.9%) eyes showed total regression of NVE, 10 
(23.3%) eyes demonstrated partial regression of NVE, 
and 12 (27.9%) eyes showed no regression of NVE. 
Thirteen (30.2%) eyes showed total regression of NVD, 
14 (32.5%) eyes demonstrated partial regression of NVD, 
and 16 (37.2%) eyes showed no regression of NVD [24]. 
Interestingly, the above 24 month neovascularization 
regression data compares unfavorably with our 
previously published six-month data [26]. This suggests 
that anti-VEGF treatment of PDR is not a permanent 
solution and that consolidation with either PRP and 
vitrectomy is needed. 
 
CONCLUSION 
Given the off-label cost effective nature of intravitreal 
bevacizumab, its clinical effectiveness and safety have 
not been as thoroughly studied as other approved similar 
drugs. Our results may add evidence that  IVB should be 
used as an adjuvant to PRP in patients with PDR, and that 
PRP and/or vitrectomy is necessary to control PDR in the 
long-run in a larger number of patients.  
 
DISCLOSURE 
The author reports no conflicts of interest in this work. 
This manuscript is part of PhD thesis on “Intravitreal 
Bevacizumab as Anti-Vascular Endothelial Growth Factor 
in the Management of Complications of Diabetic 
Retinopathy”. This study partially supported by the 
Arevalo-Coutinho Foundation for Research in 
Ophthalmology, Caracas, Venezuela. 
 
REFERENCES 
1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of 
diabetes: estimates for the year 2000 and projections for 2030. 
Diabetes Care. 2004 May;27(5):1047-53. PMID: 15111519. 
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of 
diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010 Jan;87(1):4-
14. PMID: 19896746. 
3. Michaelson IC. The Mode of Development of the Vascular System of 
the Retina, with some Observations on the Significance for Certain 
Retinal Diseases. Trans Ophthalmol Soc UK. 1948;68:137-80. 
4. Ferrara N. Vascular endothelial growth factor: basic science and 
clinical progress. Endocr Rev. 2004 Aug;25(4):581-611. PMID: 
15294883. 
5. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo 
KT. Increased vascular endothelial growth factor levels in the vitreous 
of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994 
Oct 15;118(4):445-50. PMID: 7943121. 
6. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Upregulated 
expression of vascular endothelial growth factor in proliferative 
diabetic retinopathy. Br J Ophthalmol. 1996 Mar;80(3):241-5. PMID: 
8703862. 
7. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale 
LR, Thieme H, Iwamoto MA, Park JE, et al. Vascular endothelial growth 
 
 
MEHDI Ophthalmology Journal 2013; Vol. 2, No 1  
 
23 INTRAVITREAL BEVACIZUMAB IN THE MANAGEMENT OF PROLIFERATIVE DIABETIC RETINOPATHY 
factor in ocular fluid of patients with diabetic retinopathy and other 
retinal disorders. N Engl J Med. 1994 Dec 1;331(22):1480-7. PMID: 
7526212. 
8. Malecaze F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, Favard 
C, Bayard F, Plouet J. Detection of vascular endothelial growth factor 
messenger RNA and vascular endothelial growth factor-like activity in 
proliferative diabetic retinopathy. Arch Ophthalmol. 1994 
Nov;112(11):1476-82. PMID: 7980139. 
9. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA. 
Pathologic features of vascular endothelial growth factor-induced 
retinopathy in the nonhuman primate. Am J Ophthalmol. 2002 
Mar;133(3):373-85. PMID: 11860975. 
10. Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, 
Chatzistefanou K, Ferrara N, Adamis AP. Intravitreous injections of 
vascular endothelial growth factor produce retinal ischemia and 
microangiopathy in an adult primate. Ophthalmology. 1996 
Nov;103(11):1820-8. PMID: 8942877. 
11. Fine SL, Martin DF, Kirkpatrick P. Pegaptanib sodium. Nat Rev Drug 
Discov. 2005 Mar;4(3):187-8. PMID: 15770779. 
12. Dugel PU. Ranibizumab treatment of patients with ocular diseases. 
Int Ophthalmol Clin. 2006 Fall;46(4):131-40. PMID: 17060799. 
13. Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumab-
VEGF. Drugs R D. 2002;3(1):28-30. PMID: 11881526. 
14. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography 
findings after an intravitreal injection of bevacizumab (avastin) for 
macular edema from central retinal vein occlusion. Ophthalmic Surg 
Lasers Imaging. 2005 Jul-Aug;36(4):336-9. PMID: 16156153. 
15. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence 
tomography findings after an intravitreal injection of bevacizumab 
(avastin) for neovascular age-related macular degeneration. 
Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5. PMID: 
16156152. 
16. Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, 
VEGF Trap (R1R2), VEGF Trap-Eye. Drugs R D. 2008;9(4):261-9. PMID: 
18588357. 
17. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, 
Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS; RISE and 
RIDE Research Group. Ranibizumab for diabetic macular edema: results 
from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012 
Apr;119(4):789-801. PMID: 22330964. 
18. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, 
D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD; 
Macugen Diabetic Retinopathy Study Group. A phase II randomized 
double-masked trial of pegaptanib, an anti-vascular endothelial growth 
factor aptamer, for diabetic macular edema. Ophthalmology. 2005 
Oct;112(10):1747-57. PMID: 16154196. 
19. Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS; Macugen 1013 Study 
Group. A phase 2/3, multicenter, randomized, double-masked, 2-year 
trial of pegaptanib sodium for the treatment of diabetic macular 
edema. Ophthalmology. 2011 Jun;118(6):1107-18. PMID: 21529957. 
20. Arevalo JF, Garcia-Amaris RA. Intravitreal bevacizumab for diabetic 
retinopathy. Curr Diabetes Rev. 2009 Feb;5(1):39-46. Review. PMID: 
19199897. 
21. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, 
Maia M, Berrocal MH, Solis-Vivanco A, Farah ME; Pan-American 
Collaborative Retina Study Group. Primary intravitreal bevacizumab 
(Avastin) for diabetic macular edema: results from the Pan-American 
Collaborative Retina Study Group at 6-month follow-up. 
Ophthalmology. 2007 Apr;114(4):743-50. PMID: 17398322. 
22. Arevalo JF, Sanchez JG, Fromow-Guerra J, Wu L, Berrocal MH, Farah 
ME, Cardillo J, Rodríguez FJ; Pan-American Collaborative Retina Study 
Group (PACORES). Comparison of two doses of primary intravitreal 
bevacizumab (Avastin) for diffuse diabetic macular edema: results from 
the Pan-American Collaborative Retina Study Group (PACORES) at 12-
month follow-up. Graefes Arch Clin Exp Ophthalmol. 2009 
Jun;247(6):735-43. PMID: 19189118. 
23. Arevalo JF, Sanchez JG, Lasave AF, Wu L, Maia M, Bonafonte S, Brito 
M, Alezzandrini AA, Restrepo N, Berrocal MH, Saravia M, Farah ME, 
Fromow-Guerra J, Morales-Canton V; Pan-American Collaborative 
Retina Study Group (PACORES). Intravitreal Bevacizumab (Avastin(®)) 
for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-
Planas Lecture. Curr Diabetes Rev. 2010 Sep;6(5):313-22. PMID: 
20594160. 
24. Arevalo JF, Sanchez JG, Lasave AF, Wu L, Maia M, Bonafonte S, Brito 
M, Alezzandrini AA, Restrepo N, Berrocal MH, Saravia M, Farah ME, 
Fromow-Guerra J, Morales-Canton V. Intravitreal Bevacizumab 
(Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. J 
Ophthalmol. 2011;2011:584238. PMID: 21584260. 
25. Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini AA, Brito M, 
Bonafonte S, Lujan S, Diaz-Llopis M, Restrepo N, Rodríguez FJ, 
Udaondo-Mirete P; Pan-American Collaborative Retina Study Group. 
Primary intravitreal bevacizumab for diffuse diabetic macular edema: 
the Pan-American Collaborative Retina Study Group at 24 months. 
Ophthalmology. 2009 Aug;116(8):1488-97, 1497.e1. PMID: 19545900. 
26. Arevalo JF, Wu L, Sanchez JG, Maia M, Saravia MJ, Fernandez CF, 
Evans T. Intravitreal bevacizumab (Avastin) for proliferative diabetic 
retinopathy: 6-months follow-up. Eye (Lond). 2009 Jan;23(1):117-23. 
PMID: 17891058. 
27. Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, 
Berliner AJ, Vitti R, Rückert R, Sandbrink R, Stein D, Yang K, Beckmann K, 
Heier JS. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye 
in patients with diabetic macular edema. Ophthalmology. 2011 
Sep;118(9):1819-26. PMID: 21546089. 
28. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, 
Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ; Pan American 
Collaborative Retina Group (PACORES). Twelve-month safety of 
intravitreal injections of bevacizumab (Avastin): results of the Pan-
American Collaborative Retina Study Group (PACORES). Graefes Arch 
Clin Exp Ophthalmol. 2008 Jan;246(1):81-7. PMID: 17674014. 
29. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald 
JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-
related macular degeneration. N Engl J Med. 2011 May 
19;364(20):1897-908. PMID: 21526923. 
30. Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN. The role 
of growth factors in the pathogenesis of diabetic retinopathy. Expert 
Opin Investig Drugs. 2004 Oct;13(10):1275-93. PMID: 15461557. 
 
 
MEHDI Ophthalmology Journal 2013; Vol. 2, No 1  
 
24 INTRAVITREAL BEVACIZUMAB IN THE MANAGEMENT OF PROLIFERATIVE DIABETIC RETINOPATHY 
31. Photocoagulation treatment of proliferative diabetic retinopathy. 
Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS 
Report Number 8. The Diabetic Retinopathy Study Research Group. 
Ophthalmology. 1981 Jul;88(7):583-600. PMID: 7196564. 
32. Doft BH, Blankenship GW. Single versus multiple treatment sessions 
of argon laser panretinal photocoagulation for proliferative diabetic 
retinopathy. Ophthalmology. 1982 Jul;89(7):772-9. PMID: 6181452. 
33. Tsujikawa A, Kiryu J, Dong J, Yasukawa T, Suzuma I, Takagi H, Ogura 
Y. Quantitative analysis of diabetic macular edema after scatter laser 
photocoagulation with the scanning retinal thickness analyzer. Retina. 
1999;19(1):59-64. PMID: 10048375. 
34. Fong DS, Ferris FL 3rd, Davis MD, Chew EY. Causes of severe visual 
loss in the early treatment diabetic retinopathy study: ETDRS report no. 
24. Early Treatment Diabetic Retinopathy Study Research Group. Am J 
Ophthalmol. 1999 Feb;127(2):137-41. PMID: 10030553. 
35. Kaufman SC, Ferris FL 3rd, Seigel DG, Davis MD, DeMets DL. Factors 
associated with visual outcome after photocoagulation for diabetic 
retinopathy. Diabetic Retinopathy Study Report #13. Invest Ophthalmol 
Vis Sci. 1989 Jan;30(1):23-8. PMID: 2912911. 
36. McDonald HR, Schatz H. Visual loss following panretinal 
photocoagulation for proliferative diabetic retinopathy. 
Ophthalmology. 1985 Mar;92(3):388-93. PMID: 4039432. 
37. McDonald HR, Schatz H. Macular edema following panretinal 
photocoagulation. Retina. 1985 Winter-Spring;5(1):5-10. PMID: 
4001591. 
38. Shimura M, Yasuda K, Nakazawa T, Kano T, Ohta S, Tamai M. 
Quantifying alterations of macular thickness before and after panretinal 
photocoagulation in patients with severe diabetic retinopathy and good 
vision. Ophthalmology. 2003 Dec;110(12):2386-94. PMID: 14644723. 
39. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir 
MA, Giust MJ, Wendel R, Patel A. Intravitreal bevacizumab (Avastin) in 
the treatment of proliferative diabetic retinopathy. Ophthalmology. 
2006 Oct;113(10):1695.e1-15. PMID: 17011951. 
40. Avery RL. Regression of retinal and iris neovascularization after 
intravitreal bevacizumab (Avastin) treatment. Retina. 2006 
Mar;26(3):352-4. PMID: 16508438. 
41. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment 
of proliferative diabetic retinopathy complicated by vitreous 
hemorrhage. Retina. 2006 Mar;26(3):275-8. PMID: 16508426. 
 
